Results
|
|
1.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
|
|
2.
|
Delayed Recurrent and Bilateral Breast Cancer in Patients With Partial Poland's Anomaly: Report of 2 Rare Cases and Review of the Literature. MedStar authors:
- Bozzuto, Laura M
- DeFazio, Michael V
- Dervishaj, Ornela A
Year: 2018
Citation: - Clinical Breast Cancer. 18(3):e285-e290, 2018 06.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Bozzuto LM, DeFazio MV, Dervishaj OA, Olding MJ, Pittman TA, Tousimis EA, Willey SC
|
|
|
3.
|
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. MedStar authors:
Year: 2012
Citation: - Clinical Breast Cancer. 12(4):232-9, 2012 Aug.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Intramural
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Duong QN, Hewitt SM, Hoffman HJ, Levine PH, Portera CC, Swain SM, Takikita M, Yang SX
|
|
|
4.
|
|
|
|
5.
|
|
